Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FIVHeMA: Intraventricular Fibrinolysis in Aneurysmal SAH
NCT03187405Phase 3Terminated
- Sponsor
- CHU Caen Normandie
- Start
- Feb 2018
- Primary completion
- Feb 2024
- Modality
- rProtein (Recombinant Protein), Biologic
- Countries
- 1
01
Overview
A Phase 3 trial of tissue-plasminogen activator in aneurysmal subarachnoid hemorrhage (SAH), sponsored by CHU Caen Normandie. Started Feb 2018; status: terminated.
02
Drugs
tissue-plasminogen activator
03
Conditions
aneurysmal subarachnoid hemorrhage (SAH)
Beyond the preview
Go deeper on NCT03187405.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03187405.